Financing - April 28, 2026
Ray Therapeutics raises USD 125 million, Novo Holdings doubles down on optogenetic eye gene therapy
The US company has closed an upsized, oversubscribed Series B to advance its optogenetic gene therapy pipeline for blinding retinal diseases with Novo Holdings reinforcing a strong Nordic investment footprint in late‑stage ophthalmology.
Global report - April 24, 2026
Biogen in agreement with TJ Biopharma
The companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to felzartamab in the Greater China Region.
Clinical Trials - April 15, 2026
Promising results about new Lyme disease vaccine candidate
Pfizer and Valneva's Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.
Global report - April 14, 2026
New investigation about Merck’s tactics to sustain high prices
A global investigation led by journalists from the International Consortium of Investigative Journalists shows how Merck & Co has deployed a range of strategies to sustain high prices and stifle competition.
Acquisition - April 7, 2026
MSD to acquire Terns Pharmaceuticals
MSD and Terns Pharmaceuticals have entered into a definitive agreement under which MSD, through a subsidiary, will acquire Terns for an approximate equity value of USD 6.7 billion.
Global report - April 6, 2026
Flanders punches above its weight in European biotech
The Belgian region of Flanders has long been one of Europe’s most industrially dynamic regions. Its economy is anchored by advanced manufacturing, logistics, and a life science sector that consistently performs far above the region’s size.
